Risk‐mitigating behaviours in people with inflammatory skin and joint disease during the COVID‐19 pandemic differ by treatment type: a cross‐sectional patient survey*
暂无分享,去创建一个
L. Naldi | S. Langan | I. Bruce | M. Brown | A. Cope | P. Di Meglio | N. Dand | F. Capon | S. Norton | J. Weinman | T. Torres | I. McInnes | P. Gisondi | C. Griffiths | R. Warren | P. Spuls | S. Mahil | M. Yates | J. Galloway | K. Hyrich | H. Marzo-Ortega | Z. Yiu | L. Puig | H. Bachelez | A. Vesty | H. McAteer | B. Coker | R. Sengupta | D. Jullien | J. Barker | Z. Yiu | T. Tsakok | F. Meynell | A. Vincent | M. Brown | C. Contreras | C. Lancelot | S. Langan | L. Moorhead | D. Urmston | H. Waweru | J. Weinman | J. Barker | J. Galloway | S. Mahil | J. Lambert | C. Smith | K. Mason | J. Kelly | P. Spuls | L. Puig | C. delaCruz | A. Cope | Catherine Smith | C. De La Cruz | J. Lambert | K. Hyrich | M. Brown | Matthew A Brown | S. Norton | C. Contreras | Meglio P Di | I. McKinnes | Zenas Z N Yiu | H. Waweru
[1] M. Kappelman,et al. Reply , 2021, Gastroenterology.
[2] S. Feldman,et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study , 2020, Journal of Allergy and Clinical Immunology.
[3] K. Bhaskaran,et al. Ethnic differences in COVID-19 infection, hospitalisation, and mortality: an OpenSAFELY analysis of 17 million adults in England , 2020, medRxiv.
[4] M. Feldmann,et al. Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment , 2020, The Lancet Rheumatology.
[5] E. Broadbent,et al. Mental health in the UK during the COVID-19 pandemic: cross-sectional analyses from a community cohort study , 2020, BMJ Open.
[6] G. Argenziano,et al. Patients’ demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis , 2020, PloS one.
[7] N. Barkham,et al. COVID-19 prevalence and the impact on quality of life from stringent social distancing in a single large UK rheumatology centre , 2020, Annals of the Rheumatic Diseases.
[8] S. Kraus,et al. Predictors of COVID-19 voluntary compliance behaviors: An international investigation , 2020, Global Transitions.
[9] Tokiko Watanabe,et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development , 2020, Proceedings of the National Academy of Sciences.
[10] V. Soriano,et al. Inoculum at the time of SARS-CoV-2 exposure and risk of disease severity , 2020, International Journal of Infectious Diseases.
[11] Fayzan F. Chaudhry,et al. SARS-CoV-2 viral load predicts COVID-19 mortality , 2020, The Lancet Respiratory Medicine.
[12] I. Tan,et al. FRI0520 HOSPITALIZATIONS FOR HEMATOLOGICAL MALIGNANCIES WITH RHEUMATIC DISEASES: A NATIONAL INPATIENT SAMPLE ANALYSIS OF TEN YEARS (2005-2014) , 2020, Annals of the Rheumatic Diseases.
[13] S. Ng,et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry , 2020, Gastroenterology.
[14] L. Trupin,et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry , 2020, Annals of the Rheumatic Diseases.
[15] B. Griffiths,et al. Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic. , 2020, Clinical medicine.
[16] T. Liang,et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study , 2020, BMJ.
[17] B. Pfefferbaum,et al. Mental Health and the Covid-19 Pandemic. , 2020, The New England journal of medicine.
[18] Zhicheng Wang,et al. Combating COVID-19: health equity matters , 2020, Nature Medicine.
[19] G. Onder,et al. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. , 2020, JAMA.
[20] K. Kim,et al. What Is COVID-19? , 2020, Frontiers for Young Minds.
[21] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.
[22] C. Siegel,et al. Patients' Perceive Biologics to Be Riskier and More Dreadful Than Other IBD Medications. , 2019, Inflammatory bowel diseases.
[23] M. Lebwohl,et al. Biological treatment for psoriasis and the risk of herpes zoster: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) , 2019, The Journal of dermatological treatment.
[24] Richard Inger,et al. A brief introduction to mixed effects modelling and multi-model inference in ecology , 2018, PeerJ.
[25] J. Galloway,et al. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis , 2018, Annals of the rheumatic diseases.
[26] M. Dougados,et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis , 2017, Annals of the rheumatic diseases.
[27] M. Lebwohl,et al. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). , 2015, JAMA dermatology.
[28] W. Dixon,et al. O10. Risk and Characteristics of Drug-Induced Lupus in Patients Exposed to Tumour Necrosis Factor-α Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis , 2015 .
[29] D. M. van der Heijde,et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis , 2014, Annals of the rheumatic diseases.
[30] Myrna M. Khan,et al. A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers , 2013, BMJ Open.
[31] P. Harris,et al. Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.
[32] Dennis Andersson,et al. Ensuring trust in COVID-19 data , 2021, Medicine.